Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence

PURPOSE: Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) improves overall survival (OS) in patients with Hodgkin lymphoma (HL) relative to ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy. However, the associated h...

Full description

Bibliographic Details
Main Authors: Arun Seshachalam, Shashidhar V. Karpurmath, Krishnakumar Rathnam, S. Ganapathi Raman, Murugesan Janarthinakani, Krishna Prasad, Channappa Patil, Parameswaran Anoop, Neelesh Reddy, Satish Kumar Anumula, Sirigeri Prabhakar Roopa, Krishna Reddy Golamari, Madhav Danthala, Prasad Gunari, Basawantrao Malipatil, Bharath Rangarajan, Karthik S. Udupa, Manjunath Nandennavar, Kesavan Niraimathi, Hemant Deepak Shewade
Format: Article
Language:English
Published: American Society of Clinical Oncology 2019-12-01
Series:Journal of Global Oncology
Online Access:http://ascopubs.org/doi/10.1200/JGO.19.00179

Similar Items